
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 8, 2017

BONE BIOLOGICS CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-53078
(Commission
File Number)

42-1743430
(IRS Employer
Identification No.)

2 Burlington Woods Drive, Ste 100, Burlington, MA
(Address of principal executive offices)

01803
(Zip Code)

Registrant's telephone number, including area code: **(732) 661-2224**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 1.02. Termination of a Material Definitive Agreement.

Effective January 8, 2016, the Company entered into separate Professional Services Agreements with each of Dr. Chia Soo, Dr. Eric Kang Ting and Dr. Ben Wu (collectively, the “Founders”). Pursuant to each of the Agreements, each Founder agreed to provide certain services to the Company, including providing strategic advice and strategic introductions to the Company’s management team as well as specific services set forth on an Exhibit to each Agreement. The Agreements are substantially identical. In consideration for the services to be rendered under the applicable Agreement, each Founder was granted a 10-year stock option (the “Options”) to purchase 1,800,364 shares of the Company’s common stock corresponding to 4% of the Company’s outstanding common stock, on a fully diluted basis, at an exercise price of \$1.59 per share. Additionally, beginning January 1, 2017, the Company was to pay each Founder an annual consulting fee of \$200,000 in cash or, at the option of the Company, in shares of its common stock valued as provided in the Agreement. On June 1, 2016, the Company agreed to issue to each Founder a 10-year stock option to purchase 33,105 shares of the Company’s common stock at an exercise price of \$2.05 per share as an adjustment to amounts due under the Agreements. All options issued to the Founders under the Agreements immediately terminate if the Agreements are terminated for cause.

On December 13, 2016, the Company provided written notice to each of the Founders that it was terminating the Agreements for cause, indicating that absent cure of the material breach of the Agreements, termination of the Agreements was to be effective on January 12, 2017. Despite lengthy discussions with the Founders, and multiple extensions of the termination date to accommodate such discussions, the Company was unable to resolve the outstanding issues under the Agreements, and the Company provided notice that the Agreements were terminated, effective as of April 8, 2017. The Company recognizes the possibility that one or more of the Founders may contest the Company’s right to terminate the Agreements for cause.

Dr. Soo and Dr. Wu are directors of the Company, and Dr. Ting is on the Company’s Scientific Advisory Board. Each of the Advisors was involved in the founding of the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.

Exhibit No.	Description
10.1	Bone Biologics Founder Termination Letter Soo effective April 8, 2017
10.2	Bone Biologics Founder Termination Letter Wu effective April 8, 2017
10.3	Bone Biologics Founder Termination Letter Ting effective April 8, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 11, 2017

Bone Biologics Corporation

By: /s/ STEPHEN R. LaNEVE

Name: Stephen R. LaNeve

Title: Chief Executive Officer

April 10, 2017

VIA E-MAIL

Dr. Chia Soo
115 N. Doheny Dr.
Beverly Hills, CA 90211

Re: Professional Services Agreement between Bone Biologics Corporation (the “Company”) and Dr. Chia Soo (“you” or “your”), dated January 8, 2016 (the “Agreement”).

Dear Chia:

Pursuant to that certain termination notice provided to you by the Company dated December 13, 2016, and our subsequent communications relating thereto, I confirm that the Agreement is terminated, effective as of April 8, 2017.

Please let me know if you have any questions or concerns.

Best regards,

Bone Biologics Corporation

April 10, 2017

VIA E-MAIL

Dr. Benjamin Wu
2740 Lorain Road
San Marino, CA 91108

Re: Professional Services Agreement between Bone Biologics Corporation (the “Company”) and Dr. Benjamin Wu (“you” or “your”), dated January 8, 2016 (the “Agreement”).

Dear Ben:

Pursuant to that certain termination notice provided to you by the Company dated December 13, 2016, and our subsequent communications relating thereto, I confirm that the Agreement is terminated, effective as of April 8, 2017.

Please let me know if you have any questions or concerns.

Best regards,

Bone Biologics Corporation

April 10, 2017

VIA E-MAIL

Dr. Eric Kang Ting
115 N. Doheny Dr.
Beverly Hills, CA 90211

Re: Professional Services Agreement between Bone Biologics Corporation (the “Company”) and Dr. Eric Kang Ting (“you” or “your”), dated January 8, 2016 (the “Agreement”).

Dear Eric:

Pursuant to that certain termination notice provided to you by the Company dated December 13, 2016, and our subsequent communications relating thereto, I confirm that the Agreement is terminated, effective as of April 8, 2017.

Please let me know if you have any questions or concerns.

Best regards,

Bone Biologics Corporation
